Zeda Zhang, PhD

Postdoctoral Researcher at Memorial Sloan Kettering Cancer Center, New York, NY

Zeda Zhang, PhD

Postdoctoral Researcher at Memorial Sloan Kettering Cancer Center, New York, NY

Share
Print
Share
Print
Zeda Zhang

Lab Phone

646-888-2163

Lab Fax

646-888-2595  

Dissertation

Investigating Mechanisms of Antiandrogen Resistance in Human Prostate Cancer (2020)

Start Year

2013

End Year

2020

Education

BS, Zhongshan University

Where there is great patience, care, and perseverance, there can be discovery. I learned that in my very first research experience, and the discovery of the unknown — particularly in my current area of interest, cancer biology — motivated me to pursue a PhD at Gerstner Sloan Kettering. Not only is it the best cancer program but also everyone is friendly and helpful. It is simultaneously great fun and a scientifically inspired environment.

Fellowships

The NCI Predoctoral to Postdoctoral Fellow Transition Award (NCI F99/K00) (2017-2019)

Publications

Zhang Z, Zhou C, Li X, Barnes SD, Deng S, Hoover E, Chen CC, Lee YS, Zhang Y, Wang C, Metang LA, Wu C, Tirado CR, Johnson NA, Wongvipat J, Navrazhina K, Cao Z, Choi D, Huang D, Huang CH, Linton E, Chen X, Liang Y, Mason CE, de Stanchina E, Abida W, Lujambio A, Li S, Lowe SW, Mendell JT, Malladi VS, Sawyers CL, Mu P. (2020) Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation. Cancer Cell 34, 584-598

Mao N, Gao D, Hu W, Gadal S, Hieronymus H, Wang S, Sullivan P, Zhang Z, Choi D, Rosen N, Sawyers CL, Gopalan A, Chen Y, Carver BS. (2020) Oncogenic ERG represses PI3K signaling through down-regulation of IRS2. Cancer Res. pii: canres.1394.2019 [Epub ahead of print]

Adams EJ, Karthaus WR, Hoover E, Liu D, Gruet A, Zhang Z, Cho H, DiLoreto R, Chhangawala S, Liu Y, Watson PA, Davicioni E, Sboner A, Barbieri CE, Bose R, Leslie CS, Sawyers CL (2019) FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature. doi: 10.1038/s41586-019-1318-9. [Epub ahead of print].

Bose R, Karthaus WR, Armenia J, Abida W, Iaquinta PJ, Zhang Z, Wongvipat J, Wasmuth EV, Shah N, Sullivan PS, Doran MG, Wang P, Patruno A, Zhao Y; International SU2C/PCF Prostate Cancer Dream Team, Zheng D, Schultz N, Sawyers CL. (2017) ERF mutations reveal a balance of ETS factors controlling prostate oncogenesis. Nature 546, 671-675. PMCID: PMC5576182 [Available on 2018-06-29]

Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen CC, Wongvipat J, Ku SY, Gao D, Cao Z, Shah N, Adams EJ, Abida W, Watson PA, Prandi D, Huang CH, de Stanchina E, Lowe SW, Ellis L, Beltran H, Rubin MA, Goodrich DW, Demichelis F, Sawyers CL. (2017) SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science 355, 84-88. PMCID: PMC5247742 [Available on 2017-04-06]

Gao D, Zhan Y, Di W, Moore AR, Sher JJ, Guan Y, Wang S, Zhang Z, Murphy DA, Sawyers CL, Chi P, Chen Y.(2016) A Tmprss2-CreERT2 Knock-In Mouse Model for Cancer Genetic Studies on Prostate and Colon. PLoS One 11, 0161084. PMCID: PMC4990297